rs12230440 - ADIPOR2

Magnitude 2.0 · 1 study on file

Reported associations

• Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions - Pharmacogenomics (2012) · McCormack M, Urban TJ, Shianna KV, Walley N, Pandolfo M, Depondt C, Chaila E, O'Conner GD, Kasperavičiūtė D, Radtke RA, Heinzen EL, Sisodiya SM, Delanty N, Cavalleri GL · PubMed 22379998

  ABSTRACT: Aims An association between carbamazepine-induced hypersensitivity and HLA-A3101 has been reported in populations of both European and Asian descent. We aimed to investigate HLA-A3101 and other common variants across the genome as markers for cutaneous adverse drug reactions (cADRs) attributed to lamotrigine and phenytoin. Materials & methods We recruited patients with lamotrigine-induced cADRs (n = 46) and patients with phenytoin-cADRs (n = 44) and the 1958 British birth cohort was used as a control (n = 1296). HLA-A3101 was imputed from genome-wide association study data. We applied genome-wide association to study lamotrigine- and phenytoin-induced cADR, and total cADR cases combined. Results Neither HLA-A3101 nor any other genetic marker significantly predicted lamotrigin

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.